Rebecca J. Wolsky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rebecca J. Wolsky has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin G. Bitler
Department of OB/GYN, The University of Colorado Anschutz Medical Campus, Aurora, Colorado
83 shared publications - Kimberly Jordan
Department of Immunology & Microbiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
81 shared publications - Aaron Clauset
University of Colorado Boulder
80 shared publications - Christian Rickert
Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
80 shared publications - Jennifer K. Richer
University of Colorado Anschutz Medical Campus 1 Department of Pathology Aurora, Colorado
80 shared publications - Junxiao Hu
Biostatistics Core, University of Colorado Cancer Center, 1665 Aurora Court, Suite 1032, Aurora, CO 80238, USA; Department of Pediatrics, University of Colorado School of Medicine, 13123 E 16th Ave, Aurora, CO 80045, USA
80 shared publications
Latest Publications
- Open Access
- 24 July 2026
- Published by Elsevier in SSRN Electronic Journal
Cross-Assay RNA Modeling Reveals Cancer Biomarkers
Cancer biomarker discovery is limited by small cohort sizes and the development of incompatible RNA assay platforms. Here, we systematically evaluate how to integrate data from bulk and single-cell (sc) RNA sequencing (RNA-seq), NanoString, and microarray for predictive modeling in cancer. We use high-grade serous carcinoma (HGSC) as a model system, as it is highly heterogeneous in both biology and assay data. We show that fold-change of gene expression from matched pre- and post-chemotherapy samples reduces inter-patient and inter-assay variability, but platform-specific biases persist, particularly in scRNA-seq and microarray. To optimize joint-modeling between RNA-seq and NanoString, we generate a new data set of tumor samples profiled with both assays, identifying detection limits and optimal harmonization strategies. Our approaches enable integration of cohorts for separate and combined RNA-seq and NanoString predictive models of disease recurrence (test-set AUROCs > 0.8), validated in external microarray cohorts. We leverage RNA-seq network-based analyses to provide mechanistic context for model genes, finding that GBP4 expression is a key predictor of recurrence and marks immune remodeling towards cytotoxicity. We provide an interactive web portal for data exploration. These findings establish a generalizable cross-assay harmonization of transcriptomic data and enable improved predictive modeling in heterogeneous cancers.
- 24 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessCross-Assay RNA Modeling Reveals Cancer Biomarkers
Cancer biomarker discovery is limited by small cohort sizes and the development of incompatible RNA assay platforms. Here, we systematically evaluate how to integrate data from bulk and single-cell (sc) RNA sequencing (RNA-seq), NanoString, and microarray for predictive modeling in cancer. We use high-grade serous carcinoma (HGSC) as a model system, as it is highly heterogeneous in both biology and assay data. We show that fold-change of gene expression from matched pre- and post-chemotherapy samples reduces inter-patient and inter-assay variability, but platform-specific biases persist, particularly in scRNA-seq and microarray. To optimize joint-modeling between RNA-seq and NanoString, we generate a new data set of tumor samples profiled with both assays, identifying detection limits and optimal harmonization strategies. Our approaches enable integration of cohorts for separate and combined RNA-seq and NanoString predictive models of disease recurrence (test-set AUROCs > 0.8), validated in external microarray cohorts. We leverage RNA-seq network-based analyses to provide mechanistic context for model genes, finding that GBP4 expression is a key predictor of recurrence and marks immune remodeling towards cytotoxicity. We provide an interactive web portal for data exploration. These findings establish a generalizable cross-assay harmonization of transcriptomic data and enable improved predictive modeling in heterogeneous cancers.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma
Fig S10. Example antibody staining images. Raw antibody staining images are shown here for an example FOV (FOV ID 9).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma
Fig S10. Example antibody staining images. Raw antibody staining images are shown here for an example FOV (FOV ID 9).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S14 from The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma
Table S14. Ranking of feature importance in the random forest model for only primary tumor samples. Ranking of median Gini importance values for all features across 500 evaluations predicting OS and PFS, with the model trained only on primary tumor samples.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S14 from The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma
Table S14. Ranking of feature importance in the random forest model for only primary tumor samples. Ranking of median Gini importance values for all features across 500 evaluations predicting OS and PFS, with the model trained only on primary tumor samples.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S22 from The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma
Fig S22. Random forest feature importance results split by feature type - PFS. Feature importance results for progression-free survival show in Figure 7B, split by feature type and split by subtype for spatial network features.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S22 from The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma
Fig S22. Random forest feature importance results split by feature type - PFS. Feature importance results for progression-free survival show in Figure 7B, split by feature type and split by subtype for spatial network features.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S10 from The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma
Table S10. Correlation coefficients between other cell type percentages and tumor cell percentages. Full list of Pearson correlation coefficients between tumor cell percentage and cell type percentage, two-sided p-values and false discovery rate adjusted p-values are reported, with significance determined by the latter.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S10 from The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma
Table S10. Correlation coefficients between other cell type percentages and tumor cell percentages. Full list of Pearson correlation coefficients between tumor cell percentage and cell type percentage, two-sided p-values and false discovery rate adjusted p-values are reported, with significance determined by the latter.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S14 from The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma
Fig S14. Median neighbor distances in the spatial networks. Heatmap of the median distances (μm) between spatial network neighbors of pairs of cell types aggregated across all edges included in the final set of samples.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S14 from The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma
Fig S14. Median neighbor distances in the spatial networks. Heatmap of the median distances (μm) between spatial network neighbors of pairs of cell types aggregated across all edges included in the final set of samples.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S19 from The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma
Fig S19. Random forest predictive performance results for only primary tumor samples. Main text Figure 6 repeated with random forest models trained only on primary tumor samples for the same binary outcome variables of low vs. high OS and PFS (n = 69).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S19 from The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma
Fig S19. Random forest predictive performance results for only primary tumor samples. Main text Figure 6 repeated with random forest models trained only on primary tumor samples for the same binary outcome variables of low vs. high OS and PFS (n = 69).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S20 from The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma
Fig S20. Random forest feature importance results for only primary tumor samples. Main text Figure 7 with random forest models trained only on primary tumor samples for the same binary outcome variables of low vs. high OS and PFS (n = 69).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S20 from The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma
Fig S20. Random forest feature importance results for only primary tumor samples. Main text Figure 7 with random forest models trained only on primary tumor samples for the same binary outcome variables of low vs. high OS and PFS (n = 69).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma
Fig S4. Random forest predictive performance results with increased spatial network trimming threshold. Main text Figure 6 repeated if edges in spatial networks are trimmed with a higher threshold of 100 pixels (∼48.8 μm).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma
Fig S4. Random forest predictive performance results with increased spatial network trimming threshold. Main text Figure 6 repeated if edges in spatial networks are trimmed with a higher threshold of 100 pixels (∼48.8 μm).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S11 from The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma
Table S11. Univariate Cox regression results for only primary tumor samples. Univariate Cox regression results for OS and PFS for all features, restricted to only primary tumor samples.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S11 from The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma
Table S11. Univariate Cox regression results for only primary tumor samples. Univariate Cox regression results for OS and PFS for all features, restricted to only primary tumor samples.